Personalized Adaptive Immune Modulation for Melanoma Treatment
Legal Citation
Summary of the Inventive Concept
A next-generation melanoma treatment system that integrates inflammasome inhibition, neoantigen profiling, and microRNA-based immunomodulation to achieve personalized, real-time adaptive immune response modulation.
Background and Problem Solved
The original patent's method of treating melanoma with dapansutrile has limitations in terms of efficacy and patient response variability. The new inventive concept addresses these limitations by incorporating advanced technologies to create a personalized, adaptive treatment approach that can effectively modulate the immune response to melanoma.
Detailed Description of the Inventive Concept
The inventive concept comprises a dapansutrile-based inflammasome inhibitor module, a personalized neoantigen profiling module, and a microRNA-based immunomodulation module. These modules interact to adaptively modulate the immune response to melanoma in real-time, ensuring a more effective and targeted treatment. The system can be integrated with machine learning-based algorithms, nano-particle based biosensors, and CRISPR-Cas9 systems for targeted gene editing, to further enhance its capabilities.
Novelty and Inventive Step
The new claims introduce a paradigm shift in melanoma treatment by integrating multiple advanced technologies to achieve personalized, adaptive immune response modulation. The inventive concept's novelty lies in its ability to adaptively modulate the immune response in real-time, which is not possible with the original patent's method.
Alternative Embodiments and Variations
Alternative embodiments of the inventive concept could include the use of different inflammasome inhibitors, varying neoantigen profiling techniques, or alternative microRNA-based immunomodulation approaches. The system could also be integrated with other treatment modalities, such as chemotherapy or radiation therapy, to create a comprehensive treatment strategy.
Potential Commercial Applications and Market
The inventive concept has significant commercial potential in the melanoma treatment market, which is expected to grow substantially in the coming years. The system's ability to provide personalized, adaptive treatment could lead to improved treatment outcomes and increased patient satisfaction, making it an attractive option for pharmaceutical companies, healthcare providers, and patients.
Section 103 Obviousness Analysis (PHOSITA)
Field of Art
Oncology, immunotherapy, and precision medicine with a focus on melanoma treatment and immunological modulation techniques
Person of Ordinary Skill (PHOSITA) Profile
A medical researcher or clinical oncologist with expertise in molecular biology, immunology, and cancer therapeutics, possessing advanced knowledge of inflammasome biology, targeted drug delivery, and personalized treatment strategies
Obviousness Rationale
A PHOSITA would recognize that the PTD represents a predictable extension of the source patent's dapansutrile-based melanoma treatment by incorporating known immunological modulation techniques and emerging precision medicine technologies. The disclosed system integrates standard approaches in personalized medicine, such as neoantigen profiling and immune response monitoring, which would be considered logical refinements to the original treatment method. The combination of dapansutrile with advanced immunomodulation techniques represents an incremental innovation that builds upon the foundational treatment approach disclosed in the source patent.
Obvious Combinations & Variations
Original Patent Information
| Patent Number | US 11,857,529 |
|---|---|
| Title | Methods for treating melanoma |
| Assignee(s) | OLATEC THERAPEUTICS, INC. |